Conclusion :
Gastric mucormycosis is a rare entity that affects usually predisposed
patients such as immunocompromised, alcoholic and diabetic patients but
sometimes immunocompetent ones. Its treatment is based on amphotericin B
and surgical debridment of all necrotic tissues. The mortality rates
remain high up to 85%. However, an early diagnosis and prompt therapy
can improve prognosis.